Alcon has announced a definitive agreement to acquire Lensar for approximately $356 million, strengthening its position in femtosecond laser-assisted cataract surgery (FLACS). The acquisition includes Lensar’s ALLY Robotic Cataract Laser Treatment System, Streamline software, and legacy laser technology.
Under the agreement, Alcon will pay $14 per share in cash, with the potential for an additional $2.75 per share based on procedural milestones between 2026 and 2027. If achieved, the total deal value could reach $430 million.
ALLY, which received FDA clearance in 2022 and European approval last year, is the first FDA-cleared platform enabling surgeons to perform FLACS in a single sterile environment.
Alcon CEO David Endicott highlighted the acquisition’s potential to expand access to advanced femtosecond laser technology globally, while Lensar CEO Nick Curtis emphasized the opportunity to further innovation in refractive cataract surgery.
The transaction is expected to close by late 2025, pending regulatory and shareholder approval.
Read the full press release here.
Related Content
